UNSPSC 51262402: Pronetalol or pronethalol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C15H19NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XBP4RT1IMQ, chemically known as 2-naphthalenemethanol, alpha-((isopropylamino)methyl)- but generally known as pronetalol, which bears US NIH Compound Identifier 4930. European Medicines Agency schedules Pronetalol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10092MIG. The term PRONETALOL is an International Non-Proprietary Name.

PRONETALOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Pronetalol or pronethalol bears US NLM identifiers UMLS ID C0033424 and NCI Concept Code C82257. SMILES: CC(C)NCC(C1=CC2=CC=CC=C2C=C1)O.

UNSPSC 51262402 Pronetalol or pronethalol is a Commodity code, but recent state and local procurement activity tagged under it does not align with its pharmaceutical-ingredient scope. The most recent opportunities on record involve naloxone procurement and direct-to-manufacturer prescription programs — neither of which falls within the code's nominal category of a specific beta-blocker compound.

The sourced opportunities show no current state and local solicitation activity specifically for pronetalol or pronethalol. Seminole County, Florida posted an IFB (solicitation number IFB60459723LAS) in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually, with a response deadline of July 26, 2023, but this procurement targets opioid-reversal agents, not pronetalol. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in April 2026 to explore direct-to-manufacturer prescription program capabilities, which addresses systemic pharmacy benefit structure rather than procurement of a particular pharmaceutical ingredient. Neither opportunity represents a market signal for pronetalol sourcing at the state or local level. The code shows little relevant recent activity and exhibits a mismatch between its nominal scope and the unrelated pharmaceutical procurements recorded under it.